CAPVAXIVE 4 MCG / 0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 24F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 35B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 16F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE DEOAC15B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 31 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 65 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 4 MCG / 0.5 ML · DIN 02549891 · MERCK CANADA INC
Health Canada status: MARKETED
What is CAPVAXIVE?
CAPVAXIVE 4 MCG / 0.5 ML contains PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 24F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 35B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 16F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE DEOAC15B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 31 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 65 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 4 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02549891, held by MERCK CANADA INC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 29-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CAPVAXIVE used for?
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes (3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02549891 |
|---|---|
| Brand name | CAPVAXIVE |
| Generic / active ingredient | PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 24F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 35B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 16F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE DEOAC15B : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 31 : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 65 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 4 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 4 MCG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Aug-2024 |
How is it stored and handled?
null
How is it supplied?
1 or 10 prefilled syringes packages
What can be used instead?
Other Canadian products sharing ATC code J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PREVNAR 20 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02527049 |
| VAXNEUVANCE | 30 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02522403 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00431648 |
| PNEUMOVAX 23 -(5-DOSE) | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02240632 |
| PNU-IMUNE 23 | 25 MCG / 0.5 ML | LIQUID | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | DIN 02230175 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02244081 |
| PREVNAR 13 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02335204 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02320541 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.